# Pretzel Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pretzel-therapeutics

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.pretzeltx.com
- Total disclosed funding: $66M
- Latest round: Series A (Sep 12, 2022)
- Investors on record: 11

## About

Based in Massachusetts, US, and founded by Michal Minczuk, Claes Gustafsson, Paul Thurk, and Nils-Göran Larsson, Pretzel Therapeutics, Inc., provides therapies to reverse mitochondrial dysfunction by mitochondrial biology. In September 2022, Pretzel Therapeutics, Inc., raised USD 72.5 million in series A funding led by investors, ARCH Venture Partners and Mubadala Capital, with participation from other investors Angelini Pharmaceuticals, Cambridge Enterprise, Eir Ventures, GU Ventures, GV, HealthCap, Invus, and Karolinska Institutet Holding AB.

The company offers various mitochondrial therapeutic solutions that include genome correction, genome expression modulation, and mitochondrial quality control used for the treatment of mitochondrial dysfunction. The company used gene-editing tools, DNA replication, transcription, and translation to apply therapy for genetic disorders caused by mitochondrial mutations.

The company plans to use the September 2022 funding to prosecute preclinical development and continue to build a talented team.

## Funding rounds

- Series A, Sep 12, 2022, $66M — ARCH Venture Partners, HealthCap, Cambridge Enterprise, Invus [DUP], Angelini Pharmaceuticals, GV, Cambridge Innovation Capital, Karolinska Institutet Holding AB, Mubadala Capital, GU Ventures, Eir Ventures

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- HealthCap — Series A
- Cambridge Enterprise — Series A
- Invus [DUP] — Series A
- Angelini Pharmaceuticals — Series A
- GV (https://capitalatlas.ai/funds/gv) — Series A
- Cambridge Innovation Capital (https://capitalatlas.ai/funds/cambridge-innovation-capital) — Series A
- Karolinska Institutet Holding AB — Series A
- Mubadala Capital (https://capitalatlas.ai/funds/mubadala-capital) — Series A
- GU Ventures (https://capitalatlas.ai/funds/gu-ventures) — Series A
- Eir Ventures (https://capitalatlas.ai/funds/eir-ventures) — Series A